European study initiated to compare sirolimus-eluting stenting vs. balloon angioplasty

May 14, 2008

BARCELONA, Spain - Cordis Corporation will compare its CYPHER SELECT(TM) + (Plus) Sirolimus-eluting Stent with balloon angioplasty, the company announced today at the EuroPCR meeting in Barcelona. The multicenter, prospective, randomized ACHILLES study will evaluate the performance of stenting versus balloon angioplasty in patients with below-the-knee (infrapopliteal) peripheral artery disease (PAD).

Patients with PAD have plaque buildup in their arteries, limiting proper flow and delivery of blood and oxygen to different areas of the body. Ischemic infrapopliteal arterial disease, a type of PAD, limits blood flow below the knee, causing pain, skin ulcers or sores, and an increased risk of amputation.

Dierk Scheinert, M.D., Head, Department of Angiology, University of Leipzig - Heart Center & Park Hospital said, "Peripheral artery disease is a widespread but often under diagnosed condition in Europe and around the world. It is important to understand and evaluate the safety and efficacy of treating patients less invasively with a drug-eluting stent and angioplasty opposed to angioplasty alone as we explore potential new treatment options for below-the-knee PAD." Dr. Scheinert, is principal investigator of the ACHILLES study and has served as a consultant to Cordis Corporation. He conducted the first procedure when the study was initiated in March at the University of Leipzig - Heart Center & Park Hospital.

The ACHILLES study will be conducted in 17 centers throughout Europe. Two hundred patients with new (de novo) or restenotic native lesions in arteries below the knee (i.e., tibioperoneal, anterior, posterior tibial, or peroneal) will be entered into the study and randomized on a 1:1 basis to receive the CYPHER SELECT(TM) + (Plus) Stent or balloon angioplasty, the current endovascular standard of care. All patients will undergo an X-ray examination of the blood vessels (angiography) at 12 months to assess the primary study endpoint of re-narrowing or blockage (in-segment binary restenosis).

"The safety and efficacy of the CYPHER SELECT(TM) + (Plus) Stent in treating patients with arterial obstructions in arteries where regulatory approvals have been approved has been proven through a robust clinical trial program," said Dennis Donohoe, M.D., Vice President, Worldwide Clinical Affairs, Cordis Corporation. "We are now eager to evaluate how this stent may in the future provide physicians and patients with a minimally invasive treatment option to open below-the-knee arterial blockages, which can be extremely painful and often lead to limb amputation."
About the CYPHER SELECT(TM) Plus Stent

The first next-generation drug-eluting stent, the CYPHER SELECT(TM) Stent, was launched in Europe, Asia Pacific, Latin America and Canada in 2003. The CYPHER SELECT(TM) + (Plus) Stent, the first third-generation drug-eluting stent, received the CE mark in June 2006 and is now available in many markets outside the United States.

About Cordis Corporation

Cordis Corporation, a Johnson & Johnson company, is a worldwide leader in the development and manufacture of interventional vascular technology. Through the company's innovation, research and development, Cordis partners with interventional cardiologists worldwide to treat millions of patients who suffer from vascular disease.

Edelman Public Relations

Related Angioplasty Articles from Brightsurf:

Ticagrelor was not superior to clopidogrel to reduce heart attack risk during angioplasty
A new study found the rate of heart attack and severe complications before, during or soon after elective surgery to open a blocked artery was similar between patients treated with clopidogrel and those who received the more potent antiplatelet medication ticagrelor.

Study finds significant variability in doctors' angioplasty death rates
Some doctors have higher or lower than expected death rates from coronary angioplasty procedures, also known as percutaneous coronary intervention (PCI); however, doctors should not be judged solely on the rate of patients who die from the procedure.

Beta-blockers following angioplasty show little benefit for some older patients
Following coronary angioplasty, beta-blockers did not significantly improve mortality rates or reduce the number of future cardiovascular incidents for older patients with stable angina but no history of heart attack or heart failure, according to a study published today in the JACC: Cardiovascular Interventions.

Sleep disorders may predict heart events after angioplasty
People who have had procedures to open blocked heart arteries after acute coronary syndrome (ACS) may have a higher risk of death, heart failure, heart attack and stroke if they have sleep disorders, such as sleep apnea, compared to those who don't.

Reasons for hospital-level variations in bleeding post-angioplasty are unclear
The use of bleeding avoidance strategies has only a modest effect on the variation in bleeding rates post-angioplasty among hospitals performing this procedure, leaving about 70 percent of the causes for this variation unexplained, according to a study published today in JACC: Cardiovascular Interventions.

US prediction models for kidney injury following angioplasty hold up in Japan
Models developed by the American College of Cardiology NCDR CathPCI Registry to predict the likelihood of angioplasty patients developing acute kidney injury and acute kidney injury requiring dialysis have proven to be effective among patients in Japan.

IV beta blockers before angioplasty are safe, but offer no clinical benefit
Giving intravenous beta blockers before performing a coronary angioplasty in patients who had experienced the deadliest form of heart attack -- ST-segment elevation myocardial infarction (STEMI) -- was safe but did not reduce heart attack severity or improve blood flow from the heart's main pumping chamber, according to research presented at the American College of Cardiology's 65th Annual Scientific Session.

Life-threatening bowel ischemia can often be treated by balloon angioplasty
Acute mesenteric ischemia (AMI) can be successfully treated with endovascular therapy such as balloon angioplasty, according to research from the University of Eastern Finland.

Radial access used less than femoral approach for emergency angioplasty
Although using the radial artery as the access point for angioplasty has been linked to reduced bleeding compared to use of the femoral artery, only a small number of high-risk heart attack patients who undergo rescue angioplasty -- emergency procedures following failed therapy with clot-busting drugs -- are treated by radial access, according to a study published today in the Journal of the American College of Cardiology: Cardiovascular Interventions.

Use of rarely appropriate angioplasty procedures declined sharply
The number of angioplasty procedures classified as rarely appropriate declined sharply between 2010 and 2014, as did the number of those performed on patients with non-acute conditions, according to a study published today in the Journal of the American Medical Association and simultaneously presented at a meeting of the American Heart Association in Orlando.

Read More: Angioplasty News and Angioplasty Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to